Key Drivers
- High liquidity
- No revenue
- Large cash burn
AIAI Summary
PCVX has shifted from a cash‑survival biotech into a well‑capitalized, late‑stage vaccine developer where near‑term valuation now hinges on VAX‑31 Phase‑3 OPUS readouts (late‑2026–H1‑2027) and flawless manufacturing/commercial execution—positive readouts and demonstrated scale would justify current growth valuations, while any pivotal efficacy/safety miss or production delays would rapidly compress the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •No revenue
- •Large cash burn
PCVX has strong liquidity and low leverage but no revenue, heavy R&D-driven operating losses and substantial cash burn that threaten near-term sustainability despite sizable assets and a premium market valuation. #strong-balance #cash-burn
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Support tested
- •Lower high momentum
PCVX is in a short-term downtrend over the last month, slipping about 6.5% from $58.51 to $54.72, failing to hold a breakout near $62–63 and finding near-term support around $54 that, if broken, would confirm a bearish continuation.
Sharp peak to $63.04 on 2026-02-25 followed by rapid retreat into the mid-$50s
Sentiment & News
Key News Insights:
- •Phase 3 start
- •Late 2026 toplines
- •Strong cash position
Vaxcyte finalized an FDA-aligned VAX-31 Phase 3 adult program with three pivotal studies underway (OPUS toplines due late 2026–H1 2027), advanced infant and VAX-A1 trials, expanded manufacturing capacity, and reported about $2.4B cash to fund development.
The program and cash runway materially de-risk the pipeline and could support upside in the stock, but near-term share performance will pivot on the upcoming OPUS topline results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings